The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.
The study, conducted in Malawi, Kenya, and Ghana, did not obtain informed consent from each parent whose child participated, but rather considered consent “implied” because of the particular experimental design.